Maintenance of genomic integrity is completed in the ultimate step of DNA replication and repair transactions when eukaryotic ATP-dependant DNA ligases seal DNA nicks. Ligation is a three step reaction involving (1) adenylation of a ligase active site lysine, (2) transadenylation of DNA 5′-phosphate, and (3) phosphodiester bond formation with AMP release
1,2. When ligases engage nicks harboring DNA-distorting adducts and DNA repair metabolites, including common products of abundant cellular oxidative DNA damage
3, ligation can fail at the last step, leaving 5′-adenylated DNA termini. DNA 5′-adenylation must then be reversed to prevent persistent DNA single strand breaks (SSBs) and genome instability
3,4,5. Aprataxin (Aptx) proofreads DNA ligase errors to restore ligatable DNA 5′-phosphates via a poorly understood DNA 5′-AMP hydrolase activity
3,4,5 ().
The importance of Aptx DNA processing functions in mammals is underscored by the fact that mutations in human Aprataxin (
APTX) are linked to the autosomal recessive neurological disorders Ataxia with Oculomoter Apraxia 1 (AOA1)
6,7, Ataxia with coenzyme Q10 (coQ10) deficiency
8, and additional syndromes clinically overlapping with multiple system atrophy (MSA)
9. AOA1 cells amass DNA damage with exposure to oxidative stress
5,10 or treatment with the topoismerase poison and anti-cancer drug camptothecin
11. Further evidence that budding
12 and fission yeast
13 Aptx homolog mutants confer clastogen sensitivity underlines conserved ancient Aptx DNA damage repair functions. It is hypothesized that Aptx dysfunction causes accumulation of DNA-adenylates in AOA1 patient cells, results in persistent DNA single strand breaks, and impacts the transcription apparatus
3,14,15. Both missense and truncating Aptx substitutions are linked to neurodegeneration, but how Aptx is inactivated by mutation remains unclear.
The Aptx catalytic domain is homologous to the histidine triad (HIT) family of nucleotide hydrolases and transferases
16,17. Biochemical studies support a 2-step Aptx catalytic mechanism with formation of a covalent AMP-enzyme intermediate, and disruption of DNA base-pairing proximal to the 5′-adenylate
18. Mammalian Aptx FHA domain phosphorylation-dependent protein-protein interactions with Xrcc1
19, Xrcc4
19 and MDC1
20 implicate the Aptx DNA-deadenylase action in multiple DNA repair pathways, including base excision repair (BER), single strand break repair (SSBR) and DNA double strand break repair (DSBR). Thus, Aptx repairs abortive ligation products in the context of varied DNA architectures. Aptx processes 5′-adenylated blunt and nicked DNA substrates with comparable efficiency
15 and DNaseI protection mapping of Aptx bound to adenylated and non-adenylated gapped substrates show very similar footprints, and are characterized by marked DNA binding asymmetry about the 5′-adenylation site
18. In these studies, DNA contacts are mediated almost entirely to the duplex DNA downstream of the 5′-adenylate (10-11bp of duplex downstream of a 1-base gap bearing a 5′-adenylate, and 2-3 bases of ssDNA upstream of the gap. So, critical determinants of DNA binding and catalysis involve a DNA-end interaction. A putative Aptx Zn-binding domain confers substrate interaction specificity for 5′-adenylated nicked or DNA end polynucleotide substrates
18. However, how Aptx sees adenylated nicks or DNA ends through a common dsDNA binding mode, accesses the 5′-AMP lesion, and drives direct enzymatic reversal of ligation errors remains ill-defined due to the absence of protein or protein-nucleic acid complex structural information for any Aptx homolog.
To clarify Aptx mechanism and provide insights into how Aptx is inactivated in disease, we report structural and biochemical characterizations of a Schizosaccharomyces Pombe (S. pombe) Aptx–DNA–AMP–Zn complex. Our results capture a molecular snapshot defining the salient features of the Aptx DNA-processing mechanism, provide a structural paradigm for DNA damage sensing and processing by DNA-nick and -end cleansing enzymes in the DNA damage response, and establish a molecular platform for understanding Aptx mutations in neurodegenerative disease.